BRIEF

on BIOMERIEUX (EPA:BIM)

BioMérieux Launches Salmonella Testing Kit on GENE-UP® TYPER

Stock price chart of BIOMERIEUX (EPA:BIM) showing fluctuations.

bioMérieux, a leader in in vitro diagnostics, has introduced the GENE-UP® TYPER SLM, a real-time PCR solution aimed at quickly identifying Salmonella in food industry settings. This innovation supports rapid root cause analysis, helping food manufacturers address potential contamination sources effectively. The GENE-UP® TYPER system, which combines molecular assays with a web application, offers rapid strain identification and aids in optimizing the manufacturing environment.

Salmonella enterica subspecies enterica, targeted by the new assay, is frequently associated with foodborne illnesses. By facilitating swift insights into contamination pathways, this tool aims to minimize foodborne disease outbreaks, safeguarding public health and reducing costly recalls for food companies.

This launch follows the 2025 introduction of GENE-UP® TYPER for Listeria monocytogenes and represents bioMérieux's ongoing effort to advance food safety through genomic technology and expert collaboration, particularly with Mérieux NutriSciences.

R. H.

Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all BIOMERIEUX news